Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HSV-Tk |
| Synonyms | |
| Therapy Description |
HSV-Tk (Nalotimagene carmaleucel) is a gene therapy encoding the herpes simplex virus thymidine kinase (HSV-tk), which when introduced together with ganciclovir (GCV), converts GCV to a potent cytotoxic drug that disrupts DNA replication and leads to cell death (PMID: 17327829). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HSV-Tk | Nalotimagene carmaleucel | HSV-Tk (Nalotimagene carmaleucel) is a gene therapy encoding the herpes simplex virus thymidine kinase (HSV-tk), which when introduced together with ganciclovir (GCV), converts GCV to a potent cytotoxic drug that disrupts DNA replication and leads to cell death (PMID: 17327829). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03603405 | Phase Ib/II | HSV-Tk | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | Recruiting | USA | 0 |